Maternal antiviral treatment safeguards infants from hepatitis B transmission in contingencies of delayed immunoprophylaxis.
Antiviral Agents
/ therapeutic use
Child
DNA, Viral
Female
Hepatitis B
/ drug therapy
Hepatitis B Surface Antigens
Hepatitis B e Antigens
Hepatitis B virus
/ genetics
Humans
Infant
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Pregnancy
Pregnancy Complications, Infectious
/ drug therapy
chronic hepatitis B
mother-to-child transmission
neonatal immunoprophylaxis
nucleos(t)ide analogues
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
12
01
2020
revised:
26
03
2020
accepted:
13
04
2020
pubmed:
19
4
2020
medline:
22
6
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Effectiveness of maternal antiviral prophylaxis in mother-to-child transmission of hepatitis B virus (HBV) has been extensively explored in studies where standard immunoprophylaxis is well secured to the newborns. This real-world study aims to test if maternal antiviral prophylaxis can safeguard the newborn when immunoprophylaxis administration was delayed or missed. Hepatitis B surface antigen-positive pregnant women were categorized into mothers with HBV DNA levels ≥2 × 10 From 2011 to 2017, 251 mother-child pairs were enrolled. Among 187 infants of mothers with HBV DNA levels ≥2 × 10 Antiviral prophylaxis in high viraemic mothers is effective in contingencies of missed or delayed neonatal immunoprophylaxis.
Sections du résumé
BACKGROUND & AIMS
Effectiveness of maternal antiviral prophylaxis in mother-to-child transmission of hepatitis B virus (HBV) has been extensively explored in studies where standard immunoprophylaxis is well secured to the newborns. This real-world study aims to test if maternal antiviral prophylaxis can safeguard the newborn when immunoprophylaxis administration was delayed or missed.
METHODS
Hepatitis B surface antigen-positive pregnant women were categorized into mothers with HBV DNA levels ≥2 × 10
RESULTS
From 2011 to 2017, 251 mother-child pairs were enrolled. Among 187 infants of mothers with HBV DNA levels ≥2 × 10
CONCLUSIONS
Antiviral prophylaxis in high viraemic mothers is effective in contingencies of missed or delayed neonatal immunoprophylaxis.
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2377-2384Informations de copyright
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
StevensCE, Beasley RP, Tsui J, et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med. 1975;292:771-774.
GanemD, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. Engl J Med. 2004;350:1118-1129.
SzmunessW, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-841.
NiYH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800.
ChanCY, Lee SD, Lo KJ. Legend of hepatitis B vaccination: the Taiwan experience. J Gastroenterol Hepatol. 2004;19:121-126.
PosuwanN, Wanlapakorn N, Sa-Nguanmoo P, et al. The success of a universal hepatitis B immunization program as part of Thailand's EPI after 22 years' implementation. PLoS ONE. 2016;11:e150499.
LavanchyD. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
LeeC, Gong Y, Brok J, et al. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332:328-336.
XuWM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.
ChenHL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015;62:375-386.
HanGR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215-1221.
BrownRJ, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology. 2016;63:319-333.
UnalER, Lazenby GB, Lintzenich AE, et al. Cost-effectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstet Gynecol. 2011;118:655-662.
NayagamS, Thursz M, Sicuri E, et al. Requirements for global elimination of hepatitis B: a modelling study. Lancet Infect Dis. 2016;16:1399-1408.
World Health Organization. Guidelines for the Prevention Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva, Switzerland: World Health Organization; 2015.
TerraultNA, Lok A, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis (Hoboken). 2018;12:33-34.
EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370-398.
SarinSK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98.
JourdainG, Ngo-Giang-Huong N, Harrison L, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med. 2018;378:911-923.
PanCQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis b transmission in mothers with high viral load. N Engl J Med. 2016;374:2324-2334.
Hepatitis B vaccines: WHO position paper - July 2017. Wkly Epidemiol Rec. 2017;92:369-392.
WHO. Global Hepatitis Report, 2017. Geneva, Switzerland: World Health Organization; 2017.
MiyaharaR, Jasseh M, Gomez P, et al. Barriers to timely administration of birth dose vaccines in The Gambia, West Africa. Vaccine. 2016;34:3335-3341.
ChienYC, Jan CF, Chiang CJ, Kuo HS, You SL, Chen CJ. Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccines. Hepatology. 2014;60:125-132.
SchillieS, Walker T, Veselsky S, et al. Outcomes of infants born to women infected with hepatitis B. Pediatrics. 2015;135:e1141-e1147.
BeasleyRP, Hwang LY, Lee GC, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983;2(8359):1099-1102.
SchillieS, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.
MarionSA, Tomm PM, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am J Epidemiol. 1994;140:734-746.
ZhangH, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468-476.
WHO, UNICEF. Estimates of National Immunization Coverage. Geneva, Switzerland: World Health Organization; 2014.
WHO immunization coverage. http://www.who.int/immunization/monitoring_surveillance/data/en. Accessed May, 2019.
KeaneE, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. Aliment Pharmacol Ther. 2016;44:1005-1017.
ThomasDL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380:2041-2050.
HutinY, Hennessey K, Cairns L, et al. Improving hepatitis B vaccine timely birth dose coverage: lessons from five demonstration projects in China, 2005-2009. Vaccine. 2013;31(Suppl 9):J49-J55.
ChenG, Block JM, Evans AA, Huang P, Cohen C. Gateway to Care campaign: a public health initiative to reduce the burden of hepatitis B in Haimen City, China. BMC Public Health. 2014;14:754.
VisvanathanK, Dusheiko G, Giles M, et al. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut. 2016;65(2):340-350.
LiuY, Liu H, Hu Z, et al. Hepatitis B virus virions produced under nucleos(t)ide analogue treatment are mainly not infectious because of irreversible DNA chain termination. Hepatology. 2019;71:463-476.
WangJ, Yu Y, Meng Z, et al. Reply to: "HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient". J Hepatol. 2018;68:849-851.
BrownRJ, Verna EC, Pereira MR, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol. 2012;57:953-959.